SCHEMBL23932146

SCHEMBL23932146

CN(c1ccc2ncc(-c3ccc4[nH]cnc4c3)n2n1)C1CCOCC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FYN P06241 10/20 0.47
ERN1 O75460 1/20 0.41
RIPK2 O43353 1/20 0.39
PIM1 P11309 2/20 0.39
IKBKB O14920 1/20 0.39
DYRK1A Q13627 4/20 0.38
DYRK3 O43781 3/20 0.38
CCNT1 O60563 3/20 0.38
CDK9 P50750 3/20 0.38
CDK5 Q00535 3/20 0.38
CDK5R1 Q15078 3/20 0.38
DYRK2 Q92630 3/20 0.38
DYRK1B Q9Y463 3/20 0.38
CCNA2 P20248 2/20 0.38
CDK2 P24941 2/20 0.38
MKNK1 Q9BUB5 1/20 0.38
MAP3K7 O43318 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25726401 0.85 FYN (0.65) FYNERN1RIPK2PIM1DYRK1A
SCHEMBL23932104 0.84 ERN1 (0.57) FYNERN1RIPK2PIM1DYRK1A
SCHEMBL23932050 0.84 FYN (0.56) FYNERN1RIPK2PIM1IKBKB
SCHEMBL23931890 0.83 FYN (0.44) FYNERN1RIPK2PIM1IKBKB
SCHEMBL23931952 0.82 ERN1 (0.49) FYNERN1RIPK2PIM1IKBKB
SCHEMBL23931842 0.80 ERN1 (0.43) FYNERN1RIPK2PIM1IKBKB
SCHEMBL23932159 0.80 FYN (0.47) FYNPIM1DYRK1AMKNK1
SCHEMBL23931840 0.79 FYN (0.42) FYNERN1IKBKBDYRK1AMAP3K7
SCHEMBL23931845 0.77 FYN (0.42) FYNERN1RIPK2PIM1IKBKB
SCHEMBL23932158 0.77 FYN (0.42) FYNERN1RIPK2PIM1IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435091-B2 RNA-binding protein multimerization inhibitors and methods of use thereof THE UAB RESEARCH FOUNDATION (US) 2025-10-07 US disclosed
US-20230159542-A1 RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF THE UAB RESEARCH FOUNDATION (US) 2023-05-25 US disclosed
US-20230159542-A1 RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF THE UAB RESEARCH FOUNDATION (US) 2023-05-25 US disclosed
US-20230159542-A1 RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF THE UAB RESEARCH FOUNDATION (US) 2023-05-25 US disclosed
WO-2021216757-A1 RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF THE UAB RESEARCH FOUNDATION (US) 2021-10-28 WO disclosed
WO-2021216757-A1 RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF THE UAB RESEARCH FOUNDATION (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159542-A1 RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF HNRNPR, HNRNPAB, RBM3 FYN 2657/4885ERN1 517/4885RIPK2 1665/4885
US-12435091-B2 RNA-binding protein multimerization inhibitors and methods of use thereof HNRNPR, HNRNPAB, RBM3 FYN 2657/4885ERN1 517/4885RIPK2 1665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.